Plasmalogens: a new therapeutic target in neurodegeneration

Join Biomedica for this  complimentary 2 Part Lunch and Learn:

Part 1 – Plasmalogens 101, presented by Dr John Lewis PhD (Thursday, October 14th at 12pm ADST)

In this session, join Dr John Lewis as he unpacks the fundamentals of plasmalogen biochemistry, their roles in health and disease and the clinical relevance for neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment and Parkinson’s disease.

Key learning outcomes

  • Understand the biological function of plasmalogens
  • Understand the role of plasmalogens in age-related neurodegeneration
  • Critical appraisal of clinical trial data using Hokkaido scallop derived plasmalogens
  • The application of plasmalogens in clinical practice including dosing, interactions and potential indications beyond neurodegenerative conditions.

Part 2 – A clinical approach to neurodegenerative conditions, presented by Samuel Peters, BHSc (Nat) (Thursday, November 11th, 12pm ADST

In this session, Samuel will build upon the learnings from Part 1 by providing a clinical approach to neurodegenerative disorders, providing a holistic framework for management, which can be immediately integrated into your clinical practice.

Key learning outcomes

  • An overview of the underlying drivers of age-related neurodegeneration
  • Appreciate the significance of the extended pre-clinical phase and the urgent need for early intervention
  • Understand the role of plasmalogens as well as other evidence-based complementary medicines in neurodegenerative conditions.
  • Best-practice clinical guidelines for management at various stages of disease presentation

Register here: https://www.biomedica.com.au/lunch